Unique ID issued by UMIN | UMIN000009434 |
---|---|
Receipt number | R000011088 |
Scientific Title | Clinical examination about immunoadsorption therapy for anti-myocardial autoantibodies-positive severe heart failure under the standard treatment |
Date of disclosure of the study information | 2012/11/29 |
Last modified on | 2016/09/21 17:51:45 |
Clinical examination about immunoadsorption therapy for anti-myocardial autoantibodies-positive severe heart failure under the standard treatment
Immunoadsorption examination for anti-myocardial autoantibodies
Clinical examination about immunoadsorption therapy for anti-myocardial autoantibodies-positive severe heart failure under the standard treatment
Immunoadsorption examination for anti-myocardial autoantibodies
Japan |
dilated cardiomyopathy
Cardiology |
Others
NO
To evaluate effects and safety of immunoadsorption therapy in anti-myocardial autoantibodies-positive severe heart failure patients such as dilated cardiomyopathy.
Safety,Efficacy
Exploratory
Explanatory
Phase II,III
Left ventricular ejection fraction
Body weight, 6 minutes walking test, cardio-thoracic ratio, echocardiographic parameters, and plasma ANP,BNP
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
YES
YES
Institution is considered as a block.
YES
Central registration
3
Treatment
Device,equipment |
Unconditional Treatment Group: Three months after the first course immunoadsorption (3 times), if left ventricular ejection fraction is improved by <5%, additional 5 times immunoadsorption is unconditionally performed as the second course.
Randomized Treatment Group: Three months after the first course immunoadsorption (3 times), if left ventricular ejection fraction is improved by >5%, additional 5 times immunoadsorption is performed as the second course with the randomization (1:1).
Randomized No Treatment Group: Three months after the first course immunoadsorption (3 times), if left ventricular ejection fraction is improved by >5%, additional immunoadsorption is stopped with the randomization (1:1).
18 | years-old | <= |
Not applicable |
Male and Female
NYHA 2 or 3 or 4, Left ventricular ejection fraction <40%, more than 6 months of standard medical treatments. Cardio-depressant anti-myocardial autoantibody: positive.
Patients on an ACE inhibitor which cannot be switched to an ARB, Acute myocarditis, Active infectious disease, Neoplasm, Excess alcoholic damages on liver or heart, Pregnancy.
27
1st name | |
Middle name | |
Last name | Akiyasu Baba |
Kitasato Institute
Department of Cardiology, Kitasato Institute Hospital
5-9-1 Shirokane Minato-ku, Tokyo, 108-8642 Japan
03-3444-6161
ababa68@insti.kitasato-u.ac.jp
1st name | |
Middle name | |
Last name | Akiyasu Baba |
Kitasato Institute
Department of Cardiology, Kitasato Institute Hospital
5-9-1 Shirokane Minato-ku, Tokyo, 108-8642 Japan
03-3444-6161
chiken@kitasato-u.ac.jp
Kitasato Institute Hospital, Kitasato University
MHLW
Japanese Governmental office
Japan
NO
学校法人北里研究所・北里大学・北里研究所病院循環器内科(東京都)
2012 | Year | 11 | Month | 29 | Day |
Unpublished
Completed
2012 | Year | 11 | Month | 28 | Day |
2012 | Year | 12 | Month | 01 | Day |
2016 | Year | 09 | Month | 16 | Day |
2016 | Year | 09 | Month | 30 | Day |
2016 | Year | 12 | Month | 31 | Day |
2016 | Year | 12 | Month | 31 | Day |
2012 | Year | 11 | Month | 29 | Day |
2016 | Year | 09 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011088